Bevacizumab Exacerbates Paclitaxel-Induced Neuropathy: A Retrospective Cohort Study.

Bevacizumab Exacerbates Paclitaxel-Induced Neuropathy: A Retrospective Cohort Study.

Bevacizumab (BEV), a humanized anti-vascular endothelial growth factor (VEGF) monoclonal antibody, enhances the antitumor effectiveness of paclitaxel (PTX)-based chemotherapy in many metastatic cancers. A recent study in mice showed that VEGF receptor inhibitors can interfere with the neuroprotectiv...

Full description

Bibliographic Details
Main Authors: Ayumu Matsuoka, Osamu Maeda, Takefumi Mizutani, Yasuyuki Nakano, Nobuyuki Tsunoda, Toyone Kikumori, Hidemi Goto, Yuichi Ando
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5167416?pdf=render

Internet

http://europepmc.org/articles/PMC5167416?pdf=render

Similar Items